Drug Profile
SLI F06
Alternative Names: F06-C40; Fibromodulin derived peptide - Scarless Laboratories; SLI-F06Latest Information Update: 30 Aug 2022
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer Scarless Laboratories; University of California at Los Angeles
- Class Antifibrotics; Peptides
- Mechanism of Action Collagen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Scars
Most Recent Events
- 25 Jul 2022 Phase-II clinical trials in Scars (In volunteers) in USA (Intradermal) (NCT05501327)
- 28 May 2020 No recent reports of development identified for preclinical development in Scars in USA (Intralesional, Implant)
- 18 Mar 2019 Phase-I trial for Scars in USA (Intradermal) (NCT03880058)